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participate in many essential biological processes and their dysfunc-
tion has been implicated in a variety of cardiovascular diseases
including ﬁbrosis. miR-433 has recently been implicated in renal
ﬁbrosis, however, its role in cardiac ﬁbrosis is unclear.
METHODS Cardiac ﬁbrosis were induced by TGF-b (10ng/ml, 24h)
and AngII (100nmol, 48h) on neonatal cardiac ﬁbroblasts. Quanti-
tative reverse transcription polymerase chain reactions (RT-PCRs),
immunoﬂuorescence and western blotting were used to determine
the expression levels of cardiac ﬁbrosis, includinga-SMA
and collagen. EdU and Ki-67 staining were used to evaluate cell
proliferation.
RESULTS miR-433 was increased in heart samples from dilated
cardiomyopathy patients. In addition, miR-433 was also consis-
tently upregulated in mice model of cardiac ﬁbrosis after myocar-
dial infarction or heart failure. Additionally, miR-433 was found to
be enriched in ﬁbroblasts compared to cardiomyocytes. In neonatal
cardiac ﬁbroblasts, forced expression of miR-433 promoted cell
proliferation as indicated by EdU and Ki-67 staining. Moreover,
miR-433 overexpression promoted the transdifferentiation of ﬁ-
broblasts into myoﬁbroblasts as determined for a-SMA and collagen
whether in the presence of TGF-b, AngII or not, indicating that
miR-433 is sufﬁcient to induce ﬁbrosis. In addition, knockdown of
miR-433 inhibited proliferation and the transdifferentiation into
myoﬁbroblasts, indicating that miR-433 is required for cardiac
ﬁbrosis. Interestingly, miR-433 did not affect the migration
of cardiac ﬁbroblast. Importantly, miR-433 antagomir could par-
tially attenuate cardiac ﬁbrosis induced by myocardial infarction
in mice.
CONCLUSIONS miR-433 controls cardiac ﬁbrosis both in vitro and in
vivo. Inhibition of miR-433 represents a novel therapeutic strategy
for cardiac ﬁbrosis.GW26-e3832
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OBJECTIVES The present study aimed to investigate the association
between potent rosuvastatin therapy and plaque mechanical stabili-
zation imaged by IVUSE.
METHODS 14 purebred New Zealand rabbits underwent a high-
cholesterol diet, then balloon-induced abdominal aorta endothelium
injury after 2 weeks. Seven rabbits received potent rosuvastatin
treatment for 8 weeks since the 13th week, while the seven other
rabbits took in saline. Intravascular ultrasound (IVUS) images of
abdominal aortas were acquired before and after the administration.
Each rabbit were chosen 2 obvious atherosclerotic plaques and 2
consecutive frames near the end-diastole images in situ were used to
construct an IVUS elastogram.
RESULTS Plaques in the rosuvastatin group demonstrated a stable
magnitude of sheer strain (SS) and area strain (AS) in the total plaque
(2.232.62% vs. 1.581.67%, p ¼ NS; 3.844.63% vs. 2.932.36%, p ¼
NS; respectively), but the untreated rabbits displayed a signiﬁcant
increase in the SS and AS index (1.911.05% vs. 3.541.73%,
p ¼0.005; 3.462.10% vs.5.952.59%, p ¼0.008; respectively). Dif-
ferences of the changes in SS and AS between the rosuvastatin and
control groups on serial follow-up were signiﬁcant (-0.992.83% vs.
1.151.96%, p ¼ 0.013; -1.675.05% vs. 1.252.29%, p ¼ 0.022;
respectively). SS and AS were negatively correlated with collagen
(r2 ¼ 0.341, p ¼0.001 and r2 ¼ 0.322, p ¼0.002, respectively)
and smooth muscle cell content (r2 ¼ 0.308, p ¼ 0.002 and r2 ¼
0.277, p ¼ 0.004, respectively) and positively with macrophage (r2 ¼
0.266, p ¼ 0.005 and r2 ¼ 0.198, p ¼ 0.018, respectively), lipid
content(r2 ¼ 0.388, p < 0.001 and r2 ¼ 0.357, p ¼ 0.001, respectively)
and vulnerability index (r2 ¼ 0.557, p < 0.001 and r2 ¼ 0.483, p <
0.001, respectively).
CONCLUSIONS These ﬁndings prove rosuvastatin therapy is associ-
ated with less vulnerable plaque features. IVUSE provides a technique
that may develop into a clinically available tool for detecting
vulnerable plaques and monitoring treatments.GW26-e3859
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OBJECTIVES Plasticity of vascular smooth muscle cells (VSMCs) plays
a central role in the onset and progression of proliferative vascular
diseases. In adult tissue, VSMCs exist in a physiological contractile-
quiescent phenotype, which is deﬁned by lack of the ability of pro-
liferation and migration, while high expression of contractile marker
proteins. After injury to the vessel, VSMC shifts from a contractile
phenotype to a pathological synthetic phenotype, associated with
increased proliferation, migration and matrix secretion. It has been
demonstrated that PDGF-BB is a critical mediator of VSMCs pheno-
typic switch. Atorvastatin calcium, a selective inhibitor of 3-hydroxy-
3-methyl-glutaryl l coenzyme A (HMG-CoA) reductase, exhibits
various protective effects against VSMCs. In this study, we investi-
gated the effects of atorvastatin calcium on phenotype modulation
of PDGF-BB-induced VSMCs and the related intracellular signal
transduction pathways.
METHODS VSMCs were grown to 70–80% conﬂuence and pre-
cultured in serum-free medium for 24h before treatment. Atorvastatin
calcium was dissolved in methanol for a stock solution of 100mM and
then diluted to desired concentrations with media prior to cell treat-
ment. Cells were treated with various concentrations of atorvastatin
calcium from 1 to 50M in cell proliferation assay, 10M in cell
morphology and western blotting on quiescent cells with or without
20ng/mL PDGF-BB for designated times.
RESULTS Treatment of VSMCs with atorvastatin calcium showed
dose-dependent inhibition of PDGF-BB-induced proliferation. Ator-
vastatin calcium co-treatment inhibited the phenotype modulation
and cytoskeleton rearrangements and improved the expression of
contractile phenotype marker proteins such as a-SM actin, SM22a and
calponin in comparison with PDGF-BB alone stimulated VSMCs.
Although Akt phosphorylation was strongly elicited by PDGF-BB, Akt
activation was attenuated when PDGF-BB was co-administrated
with atorvastatin calcium.
CONCLUSIONS In conclusion, atorvastatin calcium inhibits pheno-
type modulation of PDGF-BB-induced VSMCs and activation of the
Akt signaling pathway, indicating that Akt might play a vital role
in the modulation of phenotype.
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OBJECTIVES In this study the cardioprotective effect and molecular
mechanisms of tanshinone IIA were investigated.
METHODS Cardiac H9c2 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine serum. For
transfection experiments, cells were transfected with 50 nM miR-133
mimic or inhibitor; 8 hours later transfected cells were treated for 24
hours with various combination of H2O2 and tanshinone IIA as indi-
cated in ﬁgure legends. For inhibitor experiments, cells were pre-
incubated with selective PI3K inhibitor for 30 min, and then treated
with H2O2 and/or tanshinone IIA. Cell viability was determined by
CCK-8 kit. Data were presented as percentage of control. MiR-133
expression levels were relatively quantiﬁed by Bulge-Loop miRNA
qRT-PCR Primer Set in conjunction with real-time PCR with SYBR. The
relative expression of miR-133 was calculated and normalized to U6
using the comparative Ct method. Relative expression intensity
values were calculated as 2-DDCt. After treatment H9c2 cells were
harvested and lysed in RIPA lysis buffer (Applygen Technologies Inc.
Beijing, China). Then the whole cell lysates were resolved by 12%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a 0.4 um-PVDF membrane. After
blocking in 5% nonfat milk for 2 h at room temperature, the PVDF
membranes were probed with primary antibody overnight.
Following a 30 minute wash, the membranes were incubated with
secondary antibody conjugated to HRP for 1 hour at room temper-
ature. The membranes were then washed for 30 minutes and
